GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
-10.05 (-8.59%)
At close: 4:00PM EST

107.00 0.00 (0.00%)
After hours: 4:37PM EST

Stock chart is not supported by your current browser
Previous Close117.05
Bid106.99 x 2200
Ask107.38 x 800
Day's Range105.02 - 115.28
52 Week Range95.71 - 196.00
Avg. Volume582,386
Market Cap3.34B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.29
Earnings DateMay 03, 2020 - May 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est205.29
  • Why A CBD-Oil Seizure Drug Will Make — Or Break — This Biotech Stock
    Investor's Business Daily

    Why A CBD-Oil Seizure Drug Will Make — Or Break — This Biotech Stock

    GW Pharmaceuticals reported deeper-than-expected losses Tuesday and said it expects seasonality to impact its seizure medicine, Epidiolex — prodding GWPH stock to topple Wednesday.

  • Benzinga

    GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020

    GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) shares are retreating following the release of fourth-quarter results. GW Pharmaceuticals reported quarterly losses of 7 cents per share, which beat the consensus ...

  • Benzinga

    The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 25) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) (Cowen ...

  • GW Pharma's marijuana-derived epilepsy drug sales continue to climb

    GW Pharma's marijuana-derived epilepsy drug sales continue to climb

    GW Pharmaceuticals Inc. reported revenue that topped the consensus estimates Tuesday, as the company’s marijuana-derived epilepsy drug continue to grow.

  • GlobeNewswire

    GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress

    - Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full year - - Total Epidiolex® net product sales of $104.5 million for the fourth quarter.

  • GlobeNewswire

    GW Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference

    GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the Cowen 40th Annual Healthcare Conference on Tuesday, March 3rd, 2020 at 8:40 am EST. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.

  • GW Pharmaceuticals PLC (GWPH) Gains As Market Dips: What You Should Know

    GW Pharmaceuticals PLC (GWPH) Gains As Market Dips: What You Should Know

    GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $128.34, moving +1.46% from the previous trading session.

  • What's in Store for GW Pharmaceuticals' (GWPH) Q4 Earnings?

    What's in Store for GW Pharmaceuticals' (GWPH) Q4 Earnings?

    GW Pharmaceuticals (GWPH) Q4 results likely to reflect top-line growth on strong adoption of Epidiolex and Sativex.

  • GlobeNewswire

    GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Fourth Quarter and Year Ending December 31, 2019 and Host Conference Call on February 25th, 2020

    GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on February 25th, 2020 its financial results for the fourth quarter and year ending December 31st, 2019. GW will also host a conference call the same day at 4:30 p.m. ET. A replay of the call will also be available through the Company's website ( shortly after the call.

  • GW Pharmaceuticals PLC (GWPH) Outpaces Stock Market Gains: What You Should Know

    GW Pharmaceuticals PLC (GWPH) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $129.96, marking a +0.38% move from the previous day.

  • Benzinga

    Cannabis Countdown: Top 10 Marijuana Industry News Stories Of The Week

    Cannabis Countdown: Top 10 Marijuana Industry News Stories of the Week Welcome to the  Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10 Marijuana Industry News stories ...

  • Benzinga

    BofA Sees Blockbuster Sales Potential For GW Pharma's CBD Drug Epidiolex

    The update came after a teleconference call with an epilepsy specialist who treats about 260 patients, Ahmad said in a Tuesday note. Out of 45 patients on Epidiolex, four to five patients have dropped off the treatment, translating to a 10% discontinuation rate, the analyst said.

  • Here's Why GW Pharmaceuticals (NASDAQ:GWPH) Can Manage Its Debt Despite Losing Money
    Simply Wall St.

    Here's Why GW Pharmaceuticals (NASDAQ:GWPH) Can Manage Its Debt Despite Losing Money

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

  • GW Pharmaceuticals PLC (GWPH) Stock Sinks As Market Gains: What You Should Know

    GW Pharmaceuticals PLC (GWPH) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, GW Pharmaceuticals PLC (GWPH) closed at $115.46, marking a -0.06% move from the previous day.

  • MarketWatch

    GW Pharma submits supplemental NDA for Epidiolex to treat seizures from TSC

    GW Pharmaceuticals PLC said Monday it has submitted a supplemental New Drug Application (NDA) to expand the label for Epidiolex cannabidiol oral solution, CV, to include the treatment of seizures associated with Tuberous Sclerosis Complex (TSC). Epidiolex is currently indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). "The submission of this sNDA for Epidiolex is an important step towards the prospect of offering a new treatment option for those patients with TSC who battle difficult-to-treat seizures," said Chief Executive Justin Gover. GW's stock, which is still inactive in premarket trading, has tumbled 15.3% over the past three months, while the ETFMG Altnerative Harvest ETF has dropped 15.6% and the S&P 500 has gained 5.2%.

  • GlobeNewswire

    GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex® (cannabidiol) for the Treatment of Tuberous Sclerosis Complex

    GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Epidiolex® (cannabidiol) oral solution, CV. The sNDA seeks to expand the Epidiolex label to include the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic condition.

  • Investors Should Forget Aurora Cannabis and Buy GWPH Stock Instead

    Investors Should Forget Aurora Cannabis and Buy GWPH Stock Instead

    It's become increasingly clear that marijuana stock bulls made -- and continue to make -- erroneous assumptions when evaluating the potential size of the legal marijuana market. Given these errors, the valuations of most marijuana stocks, including Aurora Cannabis (NYSE:ACB), remain way too high.Source: Shutterstock There's one erroneous assumption that I'm sure you've heard. Bulls have long been saying that in our lifetimes, the cannabis market would grow as large as the alcoholic beverage market. Massive numbers of people in almost every populated area have been drinking alcoholic beverages for literally thousands of years.By contrast, in most Western countries, people have only used cannabis for recreational purposes for around 100 years.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAs a result, I recommend selling Aurora stock and all other marijuana stocks with the exception of GW Pharmaceuticals (NASDAQ:GWPH). False Cannabis AssumptionsLet's turn back to the alcoholic beverages comparison. Because of the discrepancy, there are many situations in which it is acceptable to drink but not to smoke. * 7 Stocks to Buy for February Contrarians For example, on first dates, many people would have alcoholic drinks, but very few would start smoking a joint, even in jurisdictions where cannabis is completely legal. In most cases, the same goes for a neighborhood cookout, a company holiday party, dinner at a business conference and most family gatherings. In short, drinking alcohol is just way more socially acceptable than smoking marijuana for adults in modern Western society. Consequently, marijuana consumption will never come close to alcohol consumption.Sure, many young adults experiment with cannabis and may even smoke a great deal of pot. But that trend doesn't often carry into adulthood, partly because using cannabis isn't acceptable in many social situations.Another important error was the (apparent) assumption that many or most of the people who had been obtaining cannabis illegally would be willing to pay meaningfully higher prices to obtain cannabis legally. But common sense seems to dictate that most of those who would be initially willing to buy marijuana illegally would still be willing to purchase it through unauthorized dealers after legalization.So it appears that Aurora Cannabis -- and other legal cannabis producers -- can only effectively target specific Canadians. These consumers must have no qualms about using a largely socially unacceptable drug, but also worry about buying it illegally. That explains why sales of legal cannabis have been so low. Health Issues, Legalization and Medical MarijuanaLast summer, the U.S. Food and Drug Administration warned that CBD, a component of cannabis, can be harmful. The agency stated that the compound could damage the liver or cause gastrointestinal issues. Separately, many people have gotten very sick from vaping THC, another substance in marijuana.These health issues, in my opinion, take the idea of U.S. legalization off the table for at least a decade. Many Republicans were already opposed to legalizing cannabis beforehand. Now there is almost no chance of cannabis making its way through the U.S. Senate.Those who are bullish on Aurora stock still seem to think that the U.S. will legalize marijuana in the near or medium term. But that's almost definitely not going to happen.The FDA's statement should also put a big damper on prescriptions of medical marijuana by doctors. Most doctors, for legal and medical reasons, will not want to prescribe a drug that the FDA has said could be harmful. That could apply to physicians in Canada as well as those in the U.S. The One Marijuana Stock That Is Worth Investing InGW Pharmaceuticals has developed an FDA-approved drug, Epidiolex, based on cannabinoids, which are compounds in cannabis. The company launched the drug in November 2018 as a treatment for seizures, particularly in association with Lennox-Gastaut syndrome and Dravet syndrome.The company announced preliminary 2019 revenue of $309 million, up from just $15.9 million in sales in 2018. This shows that there is strong demand for Epidiolex. GWPH is looking to get the drug approved as a treatment for tuberous sclerosis in the U.S. and Europe. It's also starting trials to test treatments for schizophrenia, post-traumatic stress disorder and multiple sclerosis-related spasticity.The market capitalization of GWPH stock is only $3.3 billion, indicating that the stock can easily rise a great deal more if the company receives more approvals. GW Pharmaceuticals also could be a takeover target for a larger drug company.As of this writing, Larry Ramer did not own shares of any of the aforementioned companies. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy for February Contrarians * 10 of the Top Franchise Stocks to Buy Now * 5 High-Yield Stocks With High Free Cash Flow Yields The post Investors Should Forget Aurora Cannabis and Buy GWPH Stock Instead appeared first on InvestorPlace.

  • 5 'Strong Buy' Biotech Stocks to Buy for 2020

    5 'Strong Buy' Biotech Stocks to Buy for 2020

    Investors seeking out high growth for their portfolios will often turn to biotech stocks. The biotechnology industry, which has become densely populated as our understanding of living systems and organisms continues to expand, has earned a reputation on Wall Street for its explosive potential ... and high volatility.In contrast to companies in other sectors, the gains and losses in even the best biotech stocks hinge less on earnings results, and more on a few key indicators such as trial-data readouts or verdicts from regulatory agencies. Product approvals unlock vital revenues, so a single positive update can function as a catalyst that propels shares to new highs.Of course, there's a reason risk-averse investors shy away from these stocks: The opposite also holds true.Wall Street pros rightly advise a cautious approach when evaluating the biotechnology industries. We find that monitoring the analyst community can be helpful on a couple fronts: For one, we can see where the pros are putting their faith. Also, analysts can provide much-needed insight into many stocks that get little media coverage, and whose progress can be difficult to gauge unless you're a medical expert.We used TipRanks' Stock Screener tool to comb through hundreds of biotechnology stocks to identify promising picks - ones that have received enough lopsided support from analysts that they earn TipRanks' top Strong Buy consensus rating. Here, we have found five top biotech stocks with overwhelmingly bullish sentiment from the analyst community, and price-growth projections of between 28% and 82%. SEE ALSO: 8 Stock Picks Getting Hit by Coronavirus Fears

  • Benzinga

    The Week In Cannabis: Stocks Rebound Hard And Many More News

    What a week for cannabis stocks! Finally rebounding, ETFs inched alongside many big companies in the industry. Over the last five trading days: The Horizons Marijuana Life Sciences Index ETF (OTC: HMLSF ...

  • Analysts: 3 Healthcare Stocks That Could Gain 35% — Or More

    Analysts: 3 Healthcare Stocks That Could Gain 35% — Or More

    Returns, that’s the name of the investing game. At the end of the day, investors are after the names that can help them generate a profit in the stock market. It’s as simple as that. The hard part, though, is determining which investment opportunities have the best chance of outperforming the market in the years to come.As not all stocks are created equal, Wall Street pros suggest doing some due diligence. This includes a close reading of what the analyst community has to say about the long-term growth prospects of a potential portfolio addition.Bearing this in mind, we applied this strategy to our own search for compelling investments in the healthcare space. With TipRanks’ Stock Screener tool, we used the sector, analyst consensus rating and price target upside filters to scan the market for the crème-de-la-crème. As a result, we pinpointed 3 buy-rated healthcare names that have received substantial support from Wall Street analysts. One more thing – each boasts over 30% upside potential from current levels. Let’s jump right in.GW Pharmaceuticals (GWPH) GW Pharmaceuticals leads the way when it comes to plant-derived cannabinoid therapeutics. It developed Epidiolex, the first cannabis plant-derived medicine to be approved by the FDA, which can be used for seizures associated with drug-resistant forms of epilepsy, Lennox-Gastaut Syndrome and Dravet Syndrome. While it has certainly struggled over the last six months, the Street is behind GWPH.On Monday, the company announced that Epidiolex revenue for the fourth quarter came in at $104 million, surpassing the $99 million consensus estimate. Not to mention this figure reflects an 18% quarter-over-quarter increase. While acknowledging that investors had expressed some doubts about the drug’s growth prospects, Cowen analyst Phil Nadeau argues that this performance should put these fears to bed.Adding to the good news, the five-star analyst believes that Epidiolex approval for tuberous sclerosis complex (TSC) is very likely. Importantly, this approval would expand its “penetration of the broader refractory epilepsy population.” As the CDC estimates there are 3.4 million people with active epilepsy in the U.S., with approximately one-third having seizures despite current regimens, the market opportunity is huge.An approval for TSC indication could also increase the average per patient dose of Epidiolex and allow for greater uptake among focal seizure patients. “These results may widen Epidiolex's dosing range by allowing physicians additional dosing flexibility for those patients who need it. The TSC data also establishes the efficacy of Epidiolex in focal seizures,” Nadeau noted.All of the above caused the analyst to conclude that the full value of the drug hasn’t been built into the share price. As a result, Nadeau reiterated an Outperform rating and $200 price target. Should the target be met, shares will be in for a 69% twelve-month gain. (To watch Nadeau’s track record, click here)What does the rest of the Street think? It turns out that they wholeheartedly agree with Nadeau. With 12 Buy ratings and no Holds or Sells, the message is clear: GWPH is a Strong Buy. If that wasn’t enough, the $200.70 average price target puts the upside potential at 69.5%. (See GW Pharmaceuticals stock analysis on TipRanks)Agios Pharmaceuticals (AGIO)Using its expertise in cellular metabolism and precision medicine, Agios Pharmaceuticals has developed a product pipeline to fight cancer and other rare genetic diseases. After it shared its vision for the company in the next five years, one analyst sees AGIO’s growth story as just getting started.Needham’s Chad Messer tells investors that management’s TIBSOVO guidance is encouraging. Expecting an increase in uptake for both the relapsed and frontline settings, the company predicts that full year 2020 sales could land within the range of $105 million to $115 million, an 80% year-over-year growth rate if achieved.With the drug currently being evaluated for further label expansion from frontline combinations in acute myeloid leukemia (AML) and approvals in myelodysplastic syndromes (MDS) and cholangiocarcinoma (CCA), the analyst thinks that TIBSOVO will be able to capture most AML patients with an IDH1 mutation in the next few years.Additionally, AGIO initiated two expansion cohorts in combination with taxanes in non-small-cell lung carcinoma (NSCLC) and pancreatic cancer in its third quarter and top-line data from both mitapivat pivotal studies should be released in 2020. “Mitapivat could be approved in adults with PKD by 2021, and in pediatric patients by 2024. Agios will also present data from the Phase II thalassemia study and provide details on a pivotal program in 2020. A Go/No-Go decision is expected for mitapivat in sickle cell anemia later this year. AG-946, a mitapivat follow-on, will enter the clinic in 2020,” Messer noted.Based on everything that the healthcare company has going for it, Messer decided to stay with the bulls, maintaining the Buy recommendation. The five-star analyst’s $71 price target implies upside potential of 35%. (To watch Messer’s track record, click here)Looking at the consensus breakdown, other analysts generally take a similar approach when it comes to AGIO. 8 Buys and 1 Hold assigned in the last three months add up to a Strong Buy consensus rating. A potential twelve-month climb of 24% could be in the cards given the $62.43 average price target. (See Agios stock analysis on TipRanks)Daré Bioscience (DARE)Following its 100% rise this week, the talk on Wall Street has shifted to Daré Bioscience. The massive gain came after the company, which develops novel therapies to improve the treatment options in women’s health, broke the news of its exclusive licensing agreement with Bayer for U.S. commercial rights to its non-hormonal, one-monthly vaginal contraceptive, Ovaprene.As part of the agreement, Daré will receive an undisclosed upfront payment, which could be up to $310 million in commercial milestones and tiered double-digit royalties. After a pivotal study is conducted, Bayer can obtain exclusive rights to commercialize Ovaprene in the U.S. If Bayer ultimately decides to make the $20 million opt-in, this will cause the exclusive license to go into effect.Maxim analyst Jason McCarthy argues that as Bayer will most likely make the $20 million payment, this deal reflects the large potential for Ovaprene. “Bayer sees the value in Ovaprene and is coming in now, with the license agreement, to be a part of the development process. This is the largest and possibly the only development stage deal in the category. We see this as validating for Ovaprene and Daré,” he explained.Given that Grand View Research estimates the contraceptive market could reach up to $11.6 billion by 2025, there is a significant opportunity. Noting that Bayer is already one of the largest players in the women’s health space, McCarthy stated, “The addition of Ovaprene is expected to expand the company’s contraceptive pipeline as the first and only non-hormonal vaginal ring product offered to women.”With this in mind, McCarthy left both his Buy rating and $3 price target as is. This conveys the analyst’s confidence in Daré’s ability to soar 94% over the next twelve months. (To watch McCarthy’s track record, click here)According to the consensus breakdown, McCarthy is the only analyst that has reviewed the stock in the last three months. To this end, the consensus rating is a Moderate Buy and the average price target matches that of McCarthy’s. However, given its impressive recent climb, more analyst ratings could be on the way.To find good ideas for healthcare stocks with solid upside potential, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Benzinga

    GW Pharma Analyst Expects $475M In Sales Of CBD Drug Expidiolex This Year

    GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) exceeded fourth-quarter estimates for Epidiolex sales, notching $108 million in revenue for the CBD drug, according to the company's preliminary figures .  The ...

  • Thomson Reuters StreetEvents

    Edited Transcript of GWPH.O earnings conference call or presentation 5-Nov-19 9:30pm GMT

    Q3 2019 GW Pharmaceuticals PLC Earnings Call


    A New Bill Would Remove a CBD Roadblock for Marijuana Companies

    A bill introduced in Congress would order the FDA to allow the marketing of CBD as a dietary supplement and food additive.